排序方式： 共有36条查询结果，搜索用时 15 毫秒
1.
目的：观察奥扎格雷钠与黄芪注射液联合治疗糖尿病肾病的疗效。方法：将84例早期糖尿病肾病患者随机分为3组，每组28例，在常规治疗的基础上，A组加用黄芪注射液，B组加用奥扎格雷钠注射液，C组加用黄芪注射液与奥扎格雷钠注射液，疗程均为20d。观察治疗前后各组尿白蛋白排泄率（UAER），血尿素氮（BUN），血清肌酐（SCr），糖化血红蛋白（HbAlc）的变化。结果：糖化血红蛋白，血清肌酐，血尿素氮，尿白蛋白排泄取：3组治疗后均比治疗前显著下降（P〈0．01），C组下降幅度优于A组和B组（P〈0．05）。结论：奥扎格雷钠联合黄芪注射液治疗糖尿病肾病能降低糖化血红蛋白，显著降低尿白蛋白排泄率，同时改善肾功能。 相似文献
2.
目的：分析尿微量白蛋白与糖尿病早期肾脏损害的关系。方法：测定尿微量采用快速金标法。结果：116例2型糖尿病病人早期尿微量白蛋白检出61例,阳性率占52．5％,结论：尿微量白蛋白检测对糖尿病人早期肾损害诊断有较重要的临床价值。 相似文献
3.
Ying-ying LU Xian YANG Wen-qing CHEN Zhen-yu JU Zhang-fei SHOU Juan JIN Xiao-hui ZHANG Jiang-hua CHEN Hong JIANG 《Journal of Zhejiang University. Science. B》2014,15(6):566-574
Aging is one of the contributing risk factors for kidney diseases. Accumulating evidence prompts the view that telomere length in kidney tissue cells is an indicator for organismal aging. Previously identified aging markers (cathelin-related antimicrobial peptide (CRAMP), stathmin, elongation factor-1α (EF-1α), and chitinase) were associated not only with telomere driven aging in mice but also with human aging and chronic diseases. This study focuses on the relationship between these biomarkers and IgA nephropathy (IgAN) progression in the Chinese population. For 260 individuals, the four markers are determined in blind datasets using direct enzyme-linked immunosorbent assay (ELISA) and immunofluorescence staining. The expression levels of CRAMP and chitinase increased in blood plasma, urine, and kidney tissues during human IgAN progression. And for the other nephropathy, such as systemic lupus erythematosus (SLE), diabetic nephropathy (DN), and focal segmental glomerulosclerosis (FSGS), there is no protein upregulation with telomere shortening. Moreover, a combination of CRAMP and chitinase can distinguish patients with IgAN from healthy individuals with 88.2%/92.5% (plasma) and 74.3%/84.2% (urine) sensitivity/specificity. These data provide the experimental evidence that telomere shortening and related inflammatory proteins are associated with human IgAN, and it could be a new direction for the disease progression study. 相似文献
4.
对肝肾疾病进行转铰蛋白(Transferren简称TF)和铜蓝蛋白(Ceruloplasmin简称CP)测定,结果表明:各组肝炎病人的TF均显著低于正常组,且谷丙转氨酶异常和HBsAg阳性者TF含量明显低于正常者,TF可作为判断肝病预后的一个指标。肾炎病人的TF也比正常人低,CP含量各组不一,肝癌患者的CP(52.44±8.73mg％)显著高于正常人(46.75±7.92mg％),乙型肝炎病人和正常组间未见差异.肝豆状核变性患者CP非常显著低于正常人,故检测CP有助于鉴别肝硬化和肝癌,同时对临床诊断肝豆状桉变性提供一项可靠的客观指标. 相似文献
5.
[目的]研究Ⅱ型糖尿病肾病(DN)患者血和尿中IL-6的含量与糖尿病微血管病变的关系。[方法]采用ELISA法对48例Ⅱ型糖尿肾病(组1)患者血液、尿液及外周单个核细胞PHA体外刺激培养上清液(CPBMCS)中的IL-6含量进行检测,并与46例肾功能正常的Ⅱ型糖尿病组(组2)及48例健康人(组3)比较。[结果]组1血和尿中的IL-6含量明显升高,其尿液中含量与组2和组3比较,分别为(P<0.01和P<0.001),血浆中含量与组2和组3比较,分别为(P<0.05和P<0.01)。组2和组3之间比较,血浆和尿液中含量无明显差异(P均>0.05),组1患者CPBMCS中的IL-6含量与组2,组3之间无明显异(P均>0.05)。[结论]血浆和尿液中IL-6的检测可作为判断Ⅱ型糖尿病肾病病情活动的一项有意义的指标。 相似文献
6.
目的：观察复方丹参滴丸对早期糖尿病性视网膜病变的治疗效果。方法：收集Ⅰ～Ⅲ期糖尿病视网膜病变患者107例，其中治疗组50例，对照组57例。治疗组服用复方丹参滴丸10粒／次，3次／d，对照组服用维生素B120mg／次、维生素C0．2g／次、维生素E0．1g／次、肌苷片0．2g／次，3次／d，连续用药6个月。观察治疗前后患者视力、视野及跟底血管造影的变化情况。结果：治疗组服药半年后与治疗前相比视力明显提高，P〈0．01；视野灰度值（MD）降低，P〈0．01；眼底微动脉瘤及出血斑数量减少，P〈0．01；两组间治疗后结果比较差异显著。结论：复方丹参滴丸对早期糖尿病性视网膜病变有明显的治疗作用，较传统复合维生素治疗效果有明显提高。 相似文献
7.
马兜铃酸的结构分析和性质研究 总被引：8，自引：0，他引：8
对马兜铃酸类的结构、检测方法、临床应用及其毒副作用进行了分析，并对马兜铃酸肾病进行了讨论。 相似文献
8.
目的:探讨四黄汤对实验性糖尿病(DM)大鼠肾脏保护作用的机理.方法:Wistar大鼠40只,链脲佐菌素(STZ)注射方法造模,将造模成功的32只大鼠随机分为模型组、四黄汤大剂量组、四黄汤小剂量组、开博通组4组,每组8只.另选8只性别、体重配对的大鼠做正常对照组.大剂量组给予四黄汤液40g/kg/d,小剂量组给予四黄汤液20g/kg/d,开博通组给予开博通混悬液10mg/kg/d,以上均每日一次,总疗程6周.实验过程中记录动物一般状态,并在最后一次给药后,禁食8h,称重后断头取血检测血糖、胰岛素、血脂、尿微量白蛋白、内皮素、血栓素等各项指标.取左肾称重,右肾固定,按常规制作石蜡切片和超薄切片,在光镜和电镜下观察肾脏病理变化.结果:四黄汤大剂量组的血糖、血脂、尿微量白蛋白、胰岛素、内皮素、血栓素各项指标均有明显改善.结论:四黄汤对实验性糖尿病(DM)大鼠肾脏有保护作用. 相似文献
9.
Hang Hu Chun-mao Han Xin-lei Hu Wan-lan Ye Wen-juan Huang Andries J. Smit 《Journal of Zhejiang University. Science. B》2012,13(5):372-377
Objective
This study was designed to evaluate the association between skin autofluorescence (AF), an indicator of advanced glycation end-products (AGEs), and foot ulcers in subjects with diabetes. 相似文献10.
Fang LIU Min WU Yan-huan FENG Hui ZHONG Tian-lei CUI You-qun HUANG Ya-ping LIANG Yong-shu DIAO Li ZANG Ling LI Jing ZANG Hong-yu QIU Song-min HUANG Ping FU 《Journal of Zhejiang University. Science. B》2013,14(11):1033-1040
The aim of this study was to understand the characteristics of blood pressure(BP)variability in subjects with diabetic nephropathy(DN),and identify the probable predictors affecting BP variability.Fifty-one chronic kidney disease(CKD)-hypertensive patients without diabetes(NDN group)and sixty type 2 diabetic patients with overt DN(DN group)were enrolled in this study.The values of short-term BP variability were obtained from 24 h ambulatory BP monitoring(ABPM).Variance analysis or nonparametric analysis revealed that 24-h systolic BP variability and nighttime systolic BP variability of the DN group were significantly higher than those of the NDN group[(12.23±3.66)vs.(10.74±3.83)mmHg,P<0.05;(11.23±4.82)vs.(9.48±3.69)mmHg,P<0.05].Then the patients of the DN group were divided into two groups according to glycated hemoglobin(HbA1c)level:Group A(HbA1c<7%)and Group B(HbA1c≥7%),and the t-test showed that patients in Group B had larger 24-h diastolic,daytime diastolic,and nighttime systolic/diastolic BP variability compared with Group A.In the DN group,partial correlation analysis revealed that HbA1c exhibited a strong association with 24-h diastolic,daytime diastolic,nighttime systolic and diastolic BP variability(P<0.001,P<0.001,P<0.05,and P<0.001,respectively).Taken together,larger short-term BP variability was detected in hypertensive type 2 diabetic patients with overt nephropathy and renal insufficiency.It may imply that the optimal BP variability level could benefit from a better glycaemic control. 相似文献